Neuron23
PrivateLast Round
Grant
Jun 17, 2026
Total Funding Raised
$312.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Neuron23 operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Grant round in June 2026.
Neuron23 is a biotechnology company that develops AI-driven drug discovery platforms and precision medicines for genetically defined neurological and immunological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neuron23 Comparables
Compare Neuron23 with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sudo Biosciences | 84% | |
| Vanqua Bio | 84% | |
| Gain Therapeutics Inc | 83% |
For institutional investors. Book with your work email.
Neuron23 Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 17, 2026 | ||||
| Series D | Jun 24, 2025 | ||||
| Series C | Mar 30, 2022 | ||||
| Series A | Dec 16, 2020 | ||||
| Series B | Dec 16, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Neuron23 Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series D, Series B |
| Surveyor Capital | Series C, Series B |
| SoftBank Investment Advisers | Series D, Series C |
| Westlake Village BioPartners | Series D, Series C, Series B, Series A |
| Cowen Private Investments | Series C, Series B |
| Perceptive Advisors | Series C, Series B |
| TD Securities | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 90% MoM.
- Jul 26, 2026
Monthly visitors increased 40% MoM, reaching 1.8K.
For institutional investors. Book with your work email.
Neuron23 Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Neuron23's valuation, stock price, and market status.
Is Neuron23 a public or private company?
Neuron23 is a private company.
What is the current stock price of Neuron23?
Neuron23 is a private company, so its shares have no public market price. Caplight tracks Neuron23's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Neuron23 worth (valuation)?
Valuation information for Neuron23 is not publicly available.
Can I buy Neuron23 stock?
Neuron23 shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Neuron23's last funding round?
Neuron23's most recent funding round was Grant on June 17, 2026.
Who are the main investors in Neuron23?
Key investors in Neuron23 include Redmile Group, SoftBank Investment Advisers, Westlake Village BioPartners, SoftBank Group, Kleiner Perkins.
Will Neuron23 IPO soon?
No public IPO plans have been announced for Neuron23.
How can I track Neuron23 secondary market activity?
Caplight tracks bids, offers, and trades in Neuron23's shares on secondary markets.